1. Home
  2. XYF vs DCTH Comparison

XYF vs DCTH Comparison

Compare XYF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$7.14

Market Cap

260.6M

Sector

Finance

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.44

Market Cap

289.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
DCTH
Founded
2014
1988
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
260.6M
289.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
XYF
DCTH
Price
$7.14
$10.44
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$22.60
AVG Volume (30 Days)
241.7K
739.3K
Earning Date
11-20-2025
11-04-2025
Dividend Yield
7.87%
N/A
EPS Growth
49.84
N/A
EPS
5.72
0.03
Revenue
$1,106,908,607.00
$79,603,000.00
Revenue This Year
N/A
$131.97
Revenue Next Year
N/A
$38.84
P/E Ratio
$1.21
$300.67
Revenue Growth
47.14
251.54
52 Week Low
$6.47
$8.12
52 Week High
$20.36
$18.23

Technical Indicators

Market Signals
Indicator
XYF
DCTH
Relative Strength Index (RSI) 29.63 62.85
Support Level $6.68 $9.59
Resistance Level $6.98 $10.14
Average True Range (ATR) 0.41 0.44
MACD 0.12 0.16
Stochastic Oscillator 45.86 87.15

Price Performance

Historical Comparison
XYF
DCTH

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: